NCT07933783Phase 2Enrolling by invitation

An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Study sponsor: Oruka Therapeutics, Inc. · ORKA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-07-01Estimated
Enrollment · participants160Estimated
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.